RPS28A Antibody

What is RPS28 and what are its primary cellular functions?

RPS28 functions as a component of the small ribosomal subunit (40S) and plays an essential role in the biogenesis of 18S rRNA. The ribosome is a large ribonucleoprotein complex responsible for protein synthesis in cells. RPS28 participates in the small subunit (SSU) processome, which serves as the first precursor of the small eukaryotic ribosomal subunit. During SSU processome assembly in the nucleolus, ribosome biogenesis factors, RNA chaperones, and ribosomal proteins like RPS28 work cooperatively to facilitate RNA folding, modifications, rearrangements, and cleavage, as well as targeted degradation of pre-ribosomal RNA by the RNA exosome .

What is the molecular weight and structural characteristics of RPS28?

RPS28 has a calculated molecular weight of approximately 8 kDa according to antibody product information . The protein is evolutionarily conserved across species and serves as a component of the 40S ribosomal subunit. Its relatively small size is typical of ribosomal proteins, which generally range from 7-30 kDa. The compact structure allows it to integrate into the complex architecture of the ribosome while performing specialized functions in rRNA processing and ribosome assembly .

What criteria should be used to select an appropriate RPS28 antibody for specific experimental applications?

When selecting an RPS28 antibody, researchers should consider:

• Application compatibility: Confirm the antibody has been validated for your specific application (WB, IHC, IP, ELISA)

• Species reactivity: Available RPS28 antibodies show validated reactivity with human, mouse, and rat samples

• Clonality and host: Both commercially available options are rabbit polyclonal antibodies, which typically offer good sensitivity but may have batch-to-batch variation

• Epitope information: Select antibodies with clearly defined immunogens - for example, ab241282 uses a synthetic peptide within Human RPS28 aa 1 to C-terminus

• Validation data: Review available validation data showing expected band size (~8 kDa) and specific detection in relevant sample types

For quantitative applications, consider antibodies with demonstrated linear signal range and minimal cross-reactivity.

What are the recommended experimental controls when using RPS28 antibodies?

Researchers should implement the following controls when working with RPS28 antibodies:

• Positive controls: Lysates from cells known to express RPS28 (virtually all eukaryotic cells)

• Negative controls:

  • Primary antibody omission control

  • IgG isotype control

  • RPS28 knockdown/knockout samples where available

• Loading controls: For Western blot, include housekeeping proteins distinct from ribosomal pathways

• Peptide competition assay: Pre-incubate antibody with immunizing peptide to confirm specificity

• Cross-species validation: If working with non-validated species, confirm cross-reactivity using sequence homology analysis

These controls are critical for distinguishing specific signal from background, especially when investigating subtle changes in RPS28 expression under different experimental conditions.

What are the optimal conditions for using RPS28 antibodies in immunohistochemistry?

For optimal IHC results with RPS28 antibodies:

• Dilution range: Use 1:20-1:200 dilution, with specific titration recommended for each experimental system

• Antigen retrieval: Primary recommendation is TE buffer at pH 9.0; alternatively, citrate buffer at pH 6.0 can be used

• Detection system: Use a sensitive detection system appropriate for the expected expression level

• Tissue considerations: Human pancreatic cancer tissue has been validated as a positive control

• Incubation conditions: Follow manufacturer's specific recommendations for temperature and duration

For optimal results, researchers should perform antibody titration within the recommended range to determine ideal concentration for their specific tissue samples .

What are the key troubleshooting approaches for Western blot applications with RPS28 antibodies?

When troubleshooting Western blot issues with RPS28 antibodies:

• No signal or weak signal:

  • Increase antibody concentration within recommended range

  • Extend incubation time (overnight at 4°C)

  • Ensure adequate protein loading (15-30 μg total protein)

  • Verify transfer efficiency with reversible staining

  • Use enhanced chemiluminescence detection

• Multiple bands or unexpected band size:

  • Verify complete sample denaturation (heating at 95°C for 5 minutes)

  • Add fresh protease inhibitors to prevent degradation

  • Optimize SDS-PAGE conditions for low molecular weight proteins (15-20% gels)

  • Consider cell-specific post-translational modifications

• High background:

  • Increase blocking time (1-2 hours or overnight)

  • Use 5% BSA instead of milk for blocking

  • Increase washing duration and frequency

  • Reduce antibody concentration

  • Test alternative secondary antibodies

Given RPS28's small size (8 kDa), use appropriate gel systems designed for low molecular weight proteins to ensure proper resolution and transfer .

How can RPS28 antibodies be used to investigate ribosome biogenesis defects?

Advanced research into ribosome biogenesis defects can leverage RPS28 antibodies through several methodological approaches:

• Subcellular localization studies:

  • Immunofluorescence to track RPS28 nucleolar-cytoplasmic distribution

  • Co-localization with nucleolar markers (fibrillarin, nucleolin) to assess pre-ribosome assembly sites

  • Time-course analysis during ribosome biogenesis inhibition

• Biochemical fractionation:

  • Sucrose gradient centrifugation to isolate different pre-ribosomal complexes

  • Western blot analysis of gradient fractions to determine RPS28 incorporation into pre-ribosomes

  • Comparison between normal and defective biogenesis conditions

• Protein-RNA interaction analysis:

  • RIP (RNA immunoprecipitation) using RPS28 antibodies to identify associated pre-rRNAs

  • Analysis of 18S rRNA processing intermediates in RPS28-depleted versus control cells

  • Correlation between RPS28 levels and 18S rRNA maturation using Northern blotting

These approaches can reveal how mutations or dysregulation in ribosome assembly factors affect RPS28 incorporation into maturing ribosomes, providing insights into molecular mechanisms of ribosomopathies .

What methodologies can be employed to study the relationship between LeuCAG3′tsRNA and RPS28 mRNA translation?

To investigate the regulatory relationship between LeuCAG3′tsRNA and RPS28 mRNA translation, researchers can employ these methodologies:

• Polysome profiling:

  • Isolate polysomes from control and LeuCAG3′tsRNA-inhibited cells

  • Fractionate on sucrose gradients and analyze RPS28 mRNA distribution

  • Quantify shifts between heavy and light polysome fractions to assess translation efficiency

  • Compare with control mRNAs (like NOP10 and GAPDH) to confirm specificity

• Target site mutagenesis:

  • Generate expression constructs with wild-type or mutated LeuCAG3′tsRNA target sites

  • Create mutations that maintain coding sequence but alter target site structure

  • Measure translational efficiency using reporter assays

  • Compare effects on target sites in coding sequence versus 3′ UTR

• RNA structure analysis:

  • Perform icSHAPE (in vivo click selective 2′-hydroxyl acylation and profiling experiment) to map mRNA structure

  • Model interaction between LeuCAG3′tsRNA and target sites

  • Compare structural changes in the presence/absence of the tsRNA

  • Identify structural elements critical for translational enhancement

These approaches can elucidate the precise mechanism by which this non-coding RNA enhances RPS28 translation, with implications for understanding ribosome biogenesis regulation .

How can differences in RPS28 protein levels be distinguished from changes in its incorporation into functional ribosomes?

Distinguishing between free RPS28 and ribosome-incorporated protein requires sophisticated analytical approaches:

• Differential centrifugation and gradient analysis:

  • Separate free proteins, ribosomal subunits, and assembled ribosomes using sucrose gradient ultracentrifugation

  • Collect fractions and analyze RPS28 distribution by Western blotting

  • Quantify the ratio of RPS28 in free versus ribosome-associated fractions

  • Compare with other ribosomal proteins to identify specific incorporation defects

• Pulse-chase analysis:

  • Metabolically label newly synthesized proteins with radioactive amino acids

  • Chase with unlabeled medium for various time periods

  • Immunoprecipitate RPS28 from different cellular fractions

  • Track the kinetics of RPS28 incorporation into ribosomes versus degradation

• Proximity labeling techniques:

  • Express RPS28 fused to a proximity labeling enzyme (BioID or APEX)

  • Identify proteins in close proximity to RPS28 under different conditions

  • Compare interactome changes that indicate altered ribosomal incorporation

As demonstrated in LeuCAG3′tsRNA inhibition studies, shifts in RPS28 mRNA from heavier to lighter polysome fractions (from 3-4 ribosomes per mRNA to 2-3 ribosomes) without changes in monosome fractions suggest regulation occurs post-initiation, providing crucial mechanistic insights .

What experimental approaches can investigate the role of RPS28 in cancer cell survival and proliferation?

To investigate RPS28's role in cancer contexts, researchers should consider these methodological approaches:

• Targeted manipulation of RPS28 levels:

  • siRNA/shRNA knockdown of RPS28 in cancer cell lines

  • CRISPR/Cas9-mediated gene editing to create partial loss-of-function models

  • LeuCAG3′tsRNA inhibition to reduce RPS28 translation

  • Monitor effects on cell viability, apoptosis, and cell cycle progression

• Patient-derived xenograft (PDX) models:

  • Establish PDX models using cancer tissues (e.g., hepatocellular carcinoma)

  • Administer LeuCAG3′tsRNA inhibitors or RPS28-targeting agents

  • Monitor tumor growth, cellular apoptosis, and ribosome biogenesis markers

  • Correlate RPS28 levels with treatment response

• Translational profiling:

  • Compare translatomes of cancer versus normal cells after RPS28 manipulation

  • Identify cancer-specific mRNAs particularly sensitive to ribosome availability

  • Analyze changes in translation of survival and proliferation factors

Research has shown that inhibition of LeuCAG3′tsRNA leads to apoptosis in human cancer cells and affects hepatocellular carcinoma PDX models, suggesting RPS28-mediated translation control might be a potential therapeutic vulnerability in certain cancers .

How conserved is RPS28 across species and what implications does this have for antibody selection?

RPS28 is highly conserved across vertebrate species, which has important implications for antibody selection and cross-species applications:

• Sequence conservation analysis:

  • Human and mouse RPS28 proteins share high sequence homology

  • Target site A in the coding sequence is almost identical between mouse and human

  • Target site B in the 3′ UTR shows greater divergence between species

• Structural conservation considerations:

  • Secondary structure of target sites differs between mouse and human despite sequence similarity

  • Human target B forms a duplex with the region straddling the translation initiation site

  • Mouse target B site does not form this particular structural arrangement

• Cross-species validation approach:

  • Test antibodies on positive control samples from each target species

  • Verify detection of the expected 8 kDa band in multiple species

  • Compare relative expression levels across species under standardized conditions

  • Perform epitope mapping to confirm conservation of antibody binding site

Currently available commercial antibodies show validated reactivity with human, mouse, and rat samples, facilitating comparative studies across these species .

What methodological considerations are important when comparing RPS28 regulation between mouse and human experimental systems?

When comparing RPS28 regulation between mouse and human systems, researchers should consider these methodological factors:

• mRNA structural differences:

  • Perform computational and experimental RNA structure analysis for both species

  • Account for differences in mRNA secondary structure that may affect regulation

  • Use icSHAPE or similar techniques to map in vivo RNA structures

• Isoform-specific analysis:

  • Identify and compare the predominant RPS28 transcript isoforms in each species

  • Design primers and antibodies that can distinguish between isoforms

  • Consider potential differences in regulatory mechanisms between isoforms

• tsRNA regulation comparison:

  • Verify LeuCAG3′tsRNA expression levels across species (similar in human HeLa and mouse Hepa 1-6 cells)

  • Compare the effects of tsRNA inhibition on RPS28 translation in both species

  • Account for differences in target site structures when interpreting results

• Translation efficiency measurement:

  • Use polysome profiling to compare baseline RPS28 translation in both species

  • Analyze ribosome density and distribution on RPS28 mRNA

  • Normalize to appropriate housekeeping genes specific to each species